Cogent Biosciences Stock Analysis
| COGT Stock | USD 9.58 0.05 0.52% |
Cogent Biosciences is overvalued with Real Value of 8.48 and Target Price of 22.11. The main objective of Cogent Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Cogent Biosciences is worth, separate from its market price. There are two main types of Cogent Biosciences' stock analysis: fundamental analysis and technical analysis.
The Cogent Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cogent Biosciences is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Cogent Stock trading window is adjusted to America/New York timezone.
Cogent |
Cogent Stock Analysis Notes
About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.48. Cogent Biosciences last dividend was issued on the 9th of November 2020. The entity had 1:4 split on the 9th of November 2020. Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cogent Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. For more info on Cogent Biosciences please contact Andrew MBA at 617 945 5576 or go to https://www.cogentbio.com.Cogent Biosciences Investment Alerts
| Cogent Biosciences generated a negative expected return over the last 90 days | |
| Cogent Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (192.41 M) with loss before overhead, payroll, taxes, and interest of (121.63 M). | |
| Cogent Biosciences currently holds about 325.56 M in cash with (153.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95. | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Ferrante Karen Jean of 2513 shares of Cogent Biosciences at 8.02 subject to Rule 16b-3 |
Cogent Biosciences Upcoming and Recent Events
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Cogent Largest EPS Surprises
Earnings surprises can significantly impact Cogent Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-02-26 | 2023-12-31 | -0.56 | -0.63 | -0.07 | 12 | ||
2021-11-10 | 2021-09-30 | -0.41 | -0.48 | -0.07 | 17 | ||
2021-08-16 | 2021-06-30 | -0.36 | -0.43 | -0.07 | 19 |
Cogent Biosciences Environmental, Social, and Governance (ESG) Scores
Cogent Biosciences' ESG score is a quantitative measure that evaluates Cogent Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Cogent Biosciences' operations that may have significant financial implications and affect Cogent Biosciences' stock price as well as guide investors towards more socially responsible investments.
Cogent Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adage Capital Partners Gp Llc | 2024-06-30 | 4.2 M | State Street Corp | 2024-06-30 | 3.8 M | Deerfield Management Co | 2024-09-30 | 3.7 M | Sofinnova Ventures | 2024-06-30 | 2.8 M | Geode Capital Management, Llc | 2024-09-30 | 2.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2 M | Saturn V Capital Management Llc | 2024-09-30 | 1.7 M | Octagon Capital Advisors Lp | 2024-09-30 | 1.3 M | Millennium Management Llc | 2024-06-30 | 1.2 M | Point72 Asset Management, L.p. | 2024-09-30 | 10.5 M | Kynam Capital Management, Lp | 2024-09-30 | 9.2 M |
Cogent Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.06 B.Cogent Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.76) | (0.79) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.75) | (0.78) |
Management Efficiency
Cogent Biosciences has return on total asset (ROA) of (0.4402) % which means that it has lost $0.4402 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7847) %, meaning that it created substantial loss on money invested by shareholders. Cogent Biosciences' management efficiency ratios could be used to measure how well Cogent Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2024. Return On Capital Employed is likely to drop to -0.79 in 2024. At this time, Cogent Biosciences' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 14.4 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 21.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.24 | 3.07 | |
| Tangible Book Value Per Share | 3.24 | 3.07 | |
| Enterprise Value Over EBITDA | (2.11) | (2.00) | |
| Price Book Value Ratio | 1.82 | 1.23 | |
| Enterprise Value Multiple | (2.11) | (2.00) | |
| Price Fair Value | 1.82 | 1.23 | |
| Enterprise Value | 502.9 M | 528.1 M |
At Cogent Biosciences, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.021 | Return On Assets (0.44) | Return On Equity (0.78) |
Technical Drivers
As of the 29th of November, Cogent Biosciences shows the Downside Deviation of 4.48, mean deviation of 2.33, and Risk Adjusted Performance of 0.0083. Cogent Biosciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cogent Biosciences Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cogent Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cogent Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cogent Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cogent Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cogent Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cogent Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cogent Biosciences Outstanding Bonds
Cogent Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cogent Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cogent bonds can be classified according to their maturity, which is the date when Cogent Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Cogent Biosciences Predictive Daily Indicators
Cogent Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cogent Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cogent Biosciences Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 7th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 3rd of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 6th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 27th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Cogent Biosciences Forecast Models
Cogent Biosciences' time-series forecasting models are one of many Cogent Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cogent Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cogent Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cogent Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cogent shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cogent Biosciences. By using and applying Cogent Stock analysis, traders can create a robust methodology for identifying Cogent entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (10.93) | (10.38) | |
| Operating Profit Margin | (12.01) | (11.41) | |
| Net Loss | (9.71) | (9.22) | |
| Gross Profit Margin | 1.15 | 1.10 |
Current Cogent Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cogent analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cogent analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 22.11 | Strong Buy | 11 | Odds |
Most Cogent analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cogent stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cogent Biosciences, talking to its executives and customers, or listening to Cogent conference calls.
Cogent Stock Analysis Indicators
Cogent Biosciences stock analysis indicators help investors evaluate how Cogent Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cogent Biosciences shares will generate the highest return on investment. By understating and applying Cogent Biosciences stock analysis, traders can identify Cogent Biosciences position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 141.1 M | |
| Common Stock Shares Outstanding | 79.7 M | |
| Total Stockholder Equity | 257.8 M | |
| Property Plant And Equipment Net | 30.3 M | |
| Cash And Short Term Investments | 265.7 M | |
| Cash | 53.2 M | |
| Accounts Payable | 10.7 M | |
| Net Debt | -34.4 M | |
| 50 Day M A | 10.7627 | |
| Total Current Liabilities | 38.2 M | |
| Other Operating Expenses | 208.1 M | |
| Non Current Assets Total | 42.7 M | |
| Non Currrent Assets Other | 4.9 M | |
| Stock Based Compensation | 30.6 M |
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.